Human Vaccines & Immunotherapeutics (Nov 2022)

Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report

  • Guang Zeng,
  • Jie Tang,
  • Shuidong Feng,
  • Liumei Xu,
  • Xiaohui Wang,
  • Zhengrong Yang

DOI
https://doi.org/10.1080/21645515.2022.2110799
Journal volume & issue
Vol. 18, no. 6

Abstract

Read online

In the global context of the COVID-19 pandemic, the overall benefits of getting any COVID-19 vaccine approved by the World Health Organization for emergency use outweigh the potential risks, even in people with weakened immune systems, including people living with HIV (PLWH). At present, there are no reports of HIV/hepatitis B virus (HBV) co-infected patients receiving a booster dose of the inactivated COVID-19 vaccine. Here, we describe a patient with HIV/HBV co-infection who did not seroconvert to three doses of the inactivated COVID-19 vaccine.

Keywords